(2023) further highlighted that HBV-positive patients with HCC exhibited variable responses to PD-1/PD-L1 inhibitors, with some benefiting from enhanced inflammatory signaling within the TME (29). The gene discussed is CD274; the disease is hepatocellular carcinoma.